Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: Comparison with voglibose and glibenclamide

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 11, 2002, Pages 1412-1416

  Mine, Tomoyuki ^a   Miura, Kyoko ^a   Kitahara, Yoshiro ^a   Okano, Akira ^a   Kawamori, Ryuzo ^b  

^a AJINOMOTO CO INC   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Goto Kakizaki rat; Insulin; Nateglinide; Postprandial; Triglyceride; Zucker fatty rat

Indexed keywords

ANTIDIABETIC AGENT; CHYLOMICRON; GLIBENCLAMIDE; INSULIN; LOW DENSITY LIPOPROTEIN; NATEGLINIDE; TRIACYLGLYCEROL; VOGLIBOSE; CYCLOHEXANE DERIVATIVE; DRUG DERIVATIVE; INOSITOL; PHENYLALANINE;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; RAT STRAIN; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; COMPARATIVE STUDY; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY; POSTPRANDIAL STATE; SPECIES DIFFERENCE; WISTAR RAT; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; CYCLOHEXANES; GLYBURIDE; HYPERTRIGLYCERIDEMIA; INOSITOL; MALE; PHENYLALANINE; POSTPRANDIAL PERIOD; RATS; RATS, WISTAR; RATS, ZUCKER; SPECIES SPECIFICITY;

EID: 1042263153     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.1412     Document Type: Article

References (24)

1. Yoshino G., Hirano T., Kazumi T., Diabetes Res. Clin. Pract., 33, 1-14 (1996).
2. Mero N., Syvanne M., Taskinen M. R., Atherosclerosis, 141 (Suppl. 1), S53-S55 (1998).
3. Ceriello A., Diabetes Metab. Res. Rev., 16, 125-132 (2000).
4. Golay A., Eur. J. Clin. Invest., 30 (Suppl. 2), 12-18 (2000).
5. Teno S., Uto Y., Nagashima H., Endoh Y., Iwamoto Y., Omori Y., Takizawa T., Diabetes Care, 23, 1401-1406 (2000).
6. Kado S., Murakami T., Aoki A., Nagase T., Katsura Y., Noritake M., Matsuoka T., Nagata N., Diabetes Res. Clin. Pract., 41, 49-55 (1998).
7. Hanefeld M., Fischer S., Spengler M., Petzinna D., Diabetes, 48 (Suppl.), A253 (1999).
8. Skrapari I., Perrea D., Ioannidis I., Karabina S. A., Elisaf M., Tselepis A. D., Karagiannacos P., Katsilambros N., Diabet Med., 18, 781-785 (2001).
9. Foley J. E., Anderson R. C., Bell P. A., Burkey B. F., Deems R. O., de Souza C., Dunning B. E., Ann. N.Y. Acad. Sci., 827, 231-245 (1997).
10. Ikenoue T., Akiyoshi M., Fujitani S., Okazaki K., Kondo N., Maki T., Br. J. Pharmacol., 120, 137-145 (1997).
11. Hu S., Wang S., Fanelli B., Bell P. A., Dunning B. E., Geisse S., Schmitz R., Boettcher B. R., J. Pharmacol. Exp. Ther., 293, 444-452 (2000).
12. Ikenoue T., Okazaki K., Fujitani S., Tsuchiya Y., Akiyoshi M., Maki T., Kondo N., Biol. Pharm. Bull., 20, 354-359 (1997).
13. Uchino H., Niwa M., Shimizu T., Nishiyama K., Kawamori R., Endocr. J., 47, 639-641 (2000).
14. Picard F., Deshaies Y., Horm. Metab. Res., 28, 377-380 (1996).
15. Fujinami K., Kojima K., Aragane K., Kusunoki J., Jpn. J. Pharmacol., 86, 127-129 (2001).
16. Hu S., Eur. J. Pharmacol., 442, 163-171 (2002).
17. Aizawa T., Sato Y., Komatsu M., Diabetes, 51 (Suppl. 1), S96-S98 (2002).
18. Kitahara Y., Akiyoshi M., Tsuchiya Y., Fujitani S., Ikenoue T., Okazaki K., Kondo N., Diabetologia, 41 (Suppl. 1), A232 (1998).
19. Steiner G., Haynes F. J., Yoshino G., Vranic M., Am. J. Physiol., 246, E187-E192 (1984).
20. Boquist S., Hamsten A., Karpe F., Ruotolo G., Diabetologia, 43, 185-193 (2000).
21. Picard F., Naimi N., Richard D., Deshaies Y., Diabetes, 48, 452-459 (1999).
22. Hikita M., Bujo H., Yamazaki K., Taira K., Takahashi K., Kobayashi J., Saito Y., Biochem. Biophys. Res. Commun., 277, 423-429 (2000).
23. The DECODE study group, Lancet, 354, 617-621 (1999).
24. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A., Diabetes Care, 22, 920-924 (1999).